Coombes, RC ; Kilburn, LS ; Snowdon, CF ; Paridaens, R ; Coleman, RE ; Jones, SE ; Jassem, J ; Van de Velde, CJH ; Delozier, T ; Alvarez, I ; Del Mastro, L 
; Ortmann, O ; Diedrich, K ; Coates, AS ; Bajetta, E ; Holmberg, SB ; Dodwell, D ; Mickiewicz, E ; Andersen, J ; Lønning, PE ; Cocconi, G ; Forbes, J ; Castiglione, M ; Stuart, N ; Stewart, A ; Fallowfield, LJ ; Bertelli, G ; Hall, E ; Bogle, RG ; Carpentieri, M ; Colajori, E ; Subar, M ; Ireland, E ; Bliss, JM
; Ortmann, O ; Diedrich, K ; Coates, AS ; Bajetta, E ; Holmberg, SB ; Dodwell, D ; Mickiewicz, E ; Andersen, J ; Lønning, PE ; Cocconi, G ; Forbes, J ; Castiglione, M ; Stuart, N ; Stewart, A ; Fallowfield, LJ ; Bertelli, G ; Hall, E ; Bogle, RG ; Carpentieri, M ; Colajori, E ; Subar, M ; Ireland, E ; Bliss, JM 
Abstract
Background Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. However, little information exists on the long-term effects of aromatase inhibitors after treatment, and whether these early improvements lead to real gains in ...
Owner only: item control page
Altmetric